<DOC>
	<DOCNO>NCT01395147</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Lu AA21004 participant major depressive disorder completion 8-week double-blind treatment period precede study ( Lu AA21004/CCT-003 ; NCT01355081 ) .</brief_summary>
	<brief_title>Long-Term Extension Study Lu AA21004 Participants With Major Depressive Disorder</brief_title>
	<detailed_description>Lu AA21004 discover H. Lundbeck A/S , co-development H. Lundbeck A/S Takeda treatment major depressive disorder general anxiety disorder . Major depressive disorder ( MDD ) chronic , recur disease considerable morbidity general population . The estimated lifetime prevalence major depression adult population 5 25 % , approximately 2-fold high prevalence woman men . The hallmark disease depress mood , additional symptom include sleep disturbance , psychomotor agitation retardation , sexual dysfunction , weight loss , concentration difficulty delusional idea . In addition direct ill effect , MDD cause suicide job loss exerts indirect influence social economy . This long-term extension study assess safety efficacy 52-week treatment Lu AA21004 participant major depressive disorder completion 8-week double-blind treatment period precede study ( LuAA21004/CCT-003 ; NCT01355081 ; hereinafter refer CCT-003 ) . This study conduct institution CCT-003 . This study include participant complete 8-week double-blind treatment period CCT-003 , meet inclusion criterion , meet exclusion criterion long-term study . Visit 1 study last visit ( Visit 7 ) 8-week double-blind treatment period CCT-003 . Participants start 2-week treatment 10 mg/day Lu AA21004 day completion 8-week double-blind treatment period CCT-003 . The dose may decrease 5 mg/day increase 20 mg/day accord response symptoms participant . A dose increase , however , allow Clinical Global Impression ( CGI ) score meet criteria dose increase investigator sub-investigator considers necessary increase dose . The dose maintain least 2 week dose change , except immediate dose reduction require safety reason . Neither dose increase 5 20 mg dose reduction 20 5 mg allow . The duration administration 52 week . Participants visit study site every 2 week first month treatment every 4 week thereafter ( Weeks 2 , 4 , 8 , 12 , 16 , 20 , 24 , 28 , 32 , 36 , 40 , 44 , 48 , 52 ) . Participants follow 4 week last dose study drug , prematurely discontinue study also follow 4 week last dose , whenever possible .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>1 . Has complete doubleblind treatment period precede study ( CCT003 ) 2 . Signs date write , informed consent form study , different precede study ( CCT003 ) . 3 . Has CGIS score improve least one point completion 8week doubleblind treatment period compare Baseline Visit precede study ( CCT003 ) . 4 . In opinion investigator , subject appear benefit longterm treatment Lu AA21004 . 1 . Diagnosed follow disorder symptom precede study ( CCT003 ) : Any current psychiatric disorder MDD define Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) . Any substancerelated disorder ( except nicotine caffeinerelated disorder ) define DSMIVTR . Clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer 's disease , Parkinson 's disease , multiple sclerosis , Huntington 's disease , etc. ) . Any DSMIVTR axis II disorder might compromise study . 2 . Is significant risk suicide , score â‰¥5 Item 10 ( suicidal thought ) MADRS attempt suicide precede study ( CCT003 )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>